文献速递临床试验与 GCP真实世界研究与卫生经济医学人工智能与信息学

HOME BP 数字干预改善高血压控制:随机对照试验

Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial.
PubMed 文献 · BMJ · 2021-01-19

HOME BP 试验在 76 家英国全科诊所纳入 622 例治疗但控制不佳的高血压患者,随机接受数字干预(自测血压+反馈+指导)或常规护理。1 年后干预组收缩压较常规组多降 3.4 mm Hg(95%CI -6.1 至 -0.8),增量成本效益比低。

要点

  • 数字干预联合自测血压可使收缩压较常规护理多降 3.4 mm Hg。
  • 干预组收缩压从 151.7 降至 138.4 mm Hg,常规组从 151.6 降至 141.8 mm Hg。
  • 增量成本效益比为每 mm Hg 降低 £11(95%CI £6 至 £29),成本较低。

核心结论

  • HOME BP 数字干预使收缩压控制优于常规护理且增量成本低。
  • 实施需整合入临床工作流并考虑数字排斥人群。

研究设计与样本

  • 非盲随机对照试验,主要终点自动判定,在英国 76 家全科诊所开展。
  • 纳入 622 例治疗但控制不佳(>140/90 mm Hg)且可上网的高血压患者。
  • 最小化算法随机分为数字干预组(305 例)或常规护理组(317 例)。

主要发现

  • 1 年后 552 例(88.6%)有数据,其余 70 例(11.4%)采用多重插补。
  • 干预组血压从 151.7/86.4 降至 138.4/80.2 mm Hg,常规组从 151.6/85.3 降至 141.8/79.8 mm Hg。
  • 收缩压平均差异 -3.4 mm Hg(95%CI -6.1 至 -0.8),舒张压平均差异 -0.5 mm Hg(-1.9 至 0.9)。
  • 完全案例分析结果可比,两组不良事件相似。
  • 增量成本效益比为每 mm Hg 降低 £11(95%CI £6 至 £29)。

关键数值与推荐

  • 干预组接受血压结果反馈给患者和专业人员,可选生活方式建议和动机支持。
  • 高血压、糖尿病及 80 岁及以上人群的目标血压遵循英国国家指南。

临床怎么用

  • 在全科诊所中可考虑采用自测血压联合数字反馈与指导管理控制不佳的高血压。
  • 实施时需将数字工具整合入临床工作流,并关注无法使用数字技术的人群。

局限性

  • 非盲设计,主要终点自动判定但受试者和研究者知晓分组。
  • 11.4% 参与者缺失主要终点数据,采用多重插补处理。
  • 试验仅纳入可上网人群,外推至数字排斥人群受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The HOME BP (Home and Online Management and Evaluation of Blood Pressure) trial aimed to test a digital intervention for hypertension management in primary care by combining self-monitoring of blood pressure with guided self-management. DESIGN: Unmasked randomised controlled trial with automated ascertainment of primary endpoint. SETTING: 76 general practices in the United Kingdom. PARTICIPANTS: 622 people with treated but poorly controlled hypertension (>140/90 mm Hg) and access to the internet. INTERVENTIONS: Participants were randomised by using a minimisation algorithm to self-monitoring of blood pressure with a digital intervention (305 participants) or usual care (routine hypertension care, with appointments and drug changes made at the discretion of the general practitioner; 317 participants). The digital intervention provided feedback of blood pressure results to patients and professionals with optional lifestyle advice and motivational support. Target blood pressure for hypertension, diabetes, and people aged 80 or older followed UK national guidelines. MAIN OUTCOME MEASURES: The primary outcome was the difference in systolic blood pressure (mean of second and third readings) after one year, adjusted for baseline blood pressure, blood pressure target, age, and practice, with multiple imputation for missing values. RESULTS: After one year, data were available from 552 participants (88.6%) with imputation for the remaining 70 participants (11.4%). Mean blood pressure dropped from 151.7/86.4 to 138.4/80.2 mm Hg in the intervention group and from 151.6/85.3 to 141.8/79.8 mm Hg in the usual care group, giving a mean difference in systolic blood pressure of -3.4 mm Hg (95% confidence interval -6.1 to -0.8 mm Hg) and a mean difference in diastolic blood pressure of -0.5 mm Hg (-1.9 to 0.9 mm Hg). Results were comparable in the complete case analysis and adverse effects were similar between groups. Within trial costs showed an incremental cost effectiveness ratio of £11 ($15, €12; 95% confidence interval £6 to £29) per mm Hg reduction. CONCLUSIONS: The HOME BP digital intervention for the management of hypertension by using self-monitored blood pressure led to better control of systolic blood pressure after one year than usual care, with low incremental costs. Implementation in primary care will require integration into clinical workflows and consideration of people who are digitally excluded. TRIAL REGISTRATION: ISRCTN13790648.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. McManus RJ, Little P, Stuart B, et al. Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial. BMJ. 2021. PMID: 33468518. doi:10.1136/bmj.m4858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。